A peer-reviewed journal aiming to publish high quality, original research articles, review papers, and case reports in the developing field of Onconephrology.
We are excited to provide high quality publications in this rapidly expansive field. We plan to bring innovative ways to deliver content. Please follow and subscribe for email alerts https://t.co/WJsN9AjUZT
@onconephsociety@ASCO@ASH_hematology@ASNKidney@nkf#onconephrology
Heavy chain deposition disease (HCDD) of the kidney in a patient of treated chronic myeloid leukemia with imatinib - @JOncoNeph https://t.co/fGSuFVoWN9
Acute kidney injury (AKI) post-mRNA SARS-CoV-2 vaccine in patients with cancer, treated with immune check point inhibitor (ICPi): An immune double whammy!
@gudnephron et al.
https://t.co/kSR2flrkny
🚨Congrats @PaulHannaMD
An Onconephrotoxin Library Collection APP for all clinicians, curated by a diverse group of expert onconephrologists and pharmacists.
Super excited to be a part of this initiative. 🥳🖥👨💻
@PITTRenal
@MayoClinicNeph@RenalFellowNtwk@TheSkeletonKG
Presenting a rare case report by @bdubNephro et al.
Vacuolar tubular injury after exposure to immune check-point inhibitor
@MDACC_RenalSec
@onconephsociety
https://t.co/caHSyd5oLl
We invite you to submit abstracts related to the the clinical care of patients with cancer and kidney disease. Authors may submit abstracts within the past 12 months. Submission deadline is August 15, 2022 to [email protected]@onconephsociety@JOncoNeph#onconephrology
A conversation between two pioneers:
In memory of Dr. Jerry Yee, we are honored to share Pioneer Series #3.
Read his masterful interview of Dr. Jolanta Malyszko. Dept Head of Nephrology @UniWarszawski@HFHNephFellow@onconephsociety
https://t.co/V8EFiaqLn6